

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet

1

of

1

Application Number

10/520,152

Filing Date

January 3, 2005

First Named Inventor

Wessling

Art Unit

1611

Examiner Name

GHALI, Isis

Attorney Docket Number

512100-2044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JEAL, W. and BENFIELD P.; Transdermal fentanyl. A review of its pharmacological properties...; Drugs, Jan. 1997; 53 (1): 109-38; Auckland, New Zealand.	
		WARD, ME et al.; Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system; Clin. Pharmacol Ther.; Dec 1997; 62 (6): 596-609; Sydney, Aust.	
		MYSTAKIDOU, K. et al.; From codeine to transdermal fentanyl for cancer pain control...; Anticancer Research; May-Jun 2001; 21 (3C): 2225-30; Athens, Greece.	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.